Last reviewed 2026-04-22 · How we verify

Dupilumab step-down

Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses.

Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps.

At a glance

Mechanism of action

Dupilumab binds to IL-4 receptor alpha, a shared component of IL-4 and IL-13 signaling pathways that drive type 2 inflammation. By blocking this receptor, it suppresses the production of IgE and other inflammatory mediators involved in allergic and atopic diseases. The 'step-down' designation refers to dose reduction or discontinuation protocols in clinical practice after disease control is achieved.

Approved indications

• Moderate-to-severe atopic dermatitis
• Moderate-to-severe asthma with type 2 inflammation
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis

Common side effects

• Injection site reactions
• Conjunctivitis
• Headache
• Oropharyngeal pain
• Upper respiratory tract infection

Key clinical trials

• Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Dupilumab step-down CI brief — competitive landscape report
• Dupilumab step-down updates RSS · CI watch RSS
• Nantes University Hospital portfolio CI